Business, energy, technology, markets and global industry news from Business News Today

American College of Gastroenterology

PharmaDeviceNews American College of Gastroenterology
Representative image of clinical biomarker analysis in a modern research laboratory, highlighting how drug developers are working to turn biological signals into regulator-accepted surrogate endpoints for faster, evidence-based clinical trials.
Pharma & Biotech

Celltrion presents LIBERTY-CD and LIBERTY-UC post hoc findings at ACG 2026

Celltrion's Zymfentra shows 71.4% Crohn's remission in a matched analysis, with new findings on treatment interruption and antibodies.

Read More
FDA Premarket Approval gives Implantica a US commercialization pathway for RefluxStop, a gastroesophageal reflux disease implant backed by long-term clinical evidence and designed to avoid encircling the esophagus. Representative image.
Pharma & Biotech

Sebela Pharmaceuticals reports positive ACG 2026 data for tegoprazan in reflux disease

Sebela's tegoprazan improves heartburn and regurgitation in Phase 3 NERD data. Examine efficacy, FDA review and competition.

Read More
Pharma & Biotech

Skyrizi reaches 73.1% remission in a Crohn’s subgroup. Can AbbVie secure a new FDA dosing option?

AbbVie reports new Skyrizi and Rinvoq Crohn's disease data, including Phase III remission results and long-term findings. Examine the evidence.

Read More